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CK = cytokeratin; EGFR = epidermal growth factor receptor; ER = oestrogen receptor; SMA = smooth muscle actin; SP = side population; TDLU =
terminal duct lobular unit.
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Abstract
Recent publications have classified breast cancers on the basis of
expression of cytokeratin-5 and -17 at the RNA and protein levels,
and demonstrated the importance of these markers in defining
sporadic tumours with bad prognosis and an association with
BRCA1-related breast cancers. These important observations
using different technology platforms produce a new functional
classification of breast carcinoma. However, it is important in
developing hypotheses about the pathogenesis of this tumour type
to review the nomenclature that is being used to emphasize
potential confusion between terminology that defines clinical
subgroups and markers of cell lineage. This article reviews the
lineages in the normal breast in relation to what have become
known as the ‘basal-like’ carcinomas.
Introduction
Human breast cancers are heterogeneous in their
morphology, response to therapy and clinical course. This
heterogeneity may originate in differences in the underlying
target cell population and/or it may be the result of different
combinations of oncogene activation and loss of tumour
suppressor gene function in a normal breast stem cell or
committed progenitor. The concept of breast cancer stem
cells and their relationship to kinetics in the normal breast
was excellently reviewed by Behbod and Rosen [1]. The
present review focuses on the characterization of the
epithelium of the normal human breast and on what we know
about the origin of breast cancer from morphological and cell
biological viewpoints. Recent expression profiling data are
considered within the context of this experimental
classification of normal and neoplastic breast tissue, and of
how these two valuable approaches are coming together to
develop a new functional classification with predictive value
for clinical behaviour and response to targeted therapies. In a
recent commentary in this journal, Wilson and Dering [2]
reviewed the current position in integrating available
microarray data in relation to pathway signatures, with an
emphasis on endocrine response. This review focuses on
how these data relate to our limited knowledge of the cell-
type origin of breast cancer.
Cell types in the normal breast: definition of a
‘basal cell’
From 28 weeks of intrauterine life the normal human breast is
composed of two cell layers, an inner luminal cell population
and a distinct outer cell layer, juxtaposed to the basement
membrane, termed the ‘basal’ layer [3]. Although the breast
ductal system is comprised of domains with distinct
morphology and function, this layered architecture is found
throughout the mammary gland from the nipple to the terminal
alveoli. This basal cell layer is morphologically heterogeneous
in that cells appear either spindle-shaped or cuboidal,
depending on their location in the branching structure of
breast ducts and on the hormonal or menopausal status of
the tissue. These cells can be distinguished from basal cells
in stratified squamous epithelium because they exhibit many
features of smooth muscle cells, including expression of
smooth muscle actin (SMA), myosin [4] and neutral
endopeptidase (CD10) [5] The term ‘myoepithelial’ cell was
coined to describe cells that express both epithelial
characteristics and these contractile proteins.
The use of the term ‘basal’ to refer to a cell population that
expresses certain high-molecular-weight cytokeratins took its
origin in the now classical papers of Moll and colleagues. In
1982 Moll, working in Werner Franke’s laboratory, described
by two-dimensional gel analysis the catalogue of human
cytokeratins in cultured cells, normal epithelia and tumours
[6]. That report also identified two main groups of breast
cancers, based on their expression of simple or stratified
epithelial cytokeratins. In 1983 Moll and coworkers [7]
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reported a more comprehensive comparison of cytokeratins
expressed in tumours and their associated normal epithelia.
This latter paper also confirmed that a small subgroup of
breast cancers express stratified epithelial cytokeratins,
including cytokeratin (CK)14 and CK17.
Over the next decade studies became more refined and
antibodies became available that were specific for different
cytokeratins, facilitating the mapping of individual cytokeratins
at the cellular level. It was recognized by many groups that
the high-molecular-weight cytokeratins CK5 and CK14,
which form in vivo complexes, are expressed in the basal
cells of stratified epithelium, and thus they became known as
‘basal’ keratins [8]. In many normal glandular epithelia, such
as the salivary glands, CK5 and CK14 are found to be
expressed in cells that sit adjacent to the basement
membrane and in a ‘basal position’ from the ducts to the
acini. Thus, in most tissues the nomenclature of a basal
position and expression of ‘basal’ keratins defines the same
population of cells. The term ‘basal’ then became
synonymous with expression of basal keratins (CK5/CK14)
rather than with a position adjacent to the basement
membrane. However, confusion has arisen by applying this
terminology in experimental model systems and in breast
tumours to define the cell of origin because changes in
intermediate filament expression can be modulated in tissue
culture [9] and because, in the breast, expressions of CK5
and CK14 are apparently not restricted to myoepithelial cells.
A major problem in the human breast literature is that there is
no consensus view that can be derived on the cell types
expressing CK5, CK14 and CK17. This may in part have
arisen from variations in antibody specificity used and
differences in staining and tissue processing schedules.
There is general agreement that myoepithelial cells do
express these proteins, but there are numerous publications
from laboratories that have clearly demonstrated staining of
luminal cells in large ducts [10] but particularly in the terminal
duct lobular unit (TDLU) complex (Fig. 1) [8,11-14]. Figure 1
was taken from one of 20 reduction mammoplasties
examined. It should be noted that there was considerable
variation within the same breast and between breasts. Some
lobules were totally negative, whereas others exhibited
occasional cells that were positive. The majority of the
staining was in luminal cells with very rare weak staining of
myoepithelial cells. A limited study of in situ carcinomas, with
the same reagents, demonstrated a clear positivity in the
myoepithelial cells when associated with in situ malignancy.
A similar switch from luminal to myoepithelial cell staining has
been seen with another protein that forms part of the ‘basal-
like’ gene signature, namely annexin VIII (Stein and
coworkers, unpublished observation). In terms of comparative
pathology, it is of interest that in the mouse CK14 has also
been demonstrated in a defined subpopulation of luminal
cells [15]. However, it is a consistent finding, using both
immunocytochemistry and proteomic analysis of separated
myoepithelial cells and luminal cells [16], that CK8 and CK18
are only expressed in luminal cells. This very careful
proteomic study also demonstrated multiple keratin isoforms
and the presence of significant levels of CK5, CK14 and
CK17 in isolated luminal cells.
In the breast the term ‘basal’ thus has acquired two
meanings. In one context it has become synonymous with
breast myoepithelium and in the other it defines a specific
subpopulation of ‘basal’ cytokeratin expressing cells that
counter-intuitively may be found in either a luminal or basal
location in normal glands.
Lineages in the normal breast?
The classic morphological work conducted by Wellings and
coworkers [17-19], using whole mount preparations, clearly
demonstrated that the majority of human breast cancers arise
from the TDLU and not from the ductal system. Unfortunately,
pathologists have consistently referred to two major
subgroups of breast cancer as ductal and lobular
carcinomas, both when invasive and in situ. The current
evidence supports the contention that differences in
morphology result from secondary genetic events [20,21]
rather than a difference in the target cell, although the target
cell for either major grouping has not been defined. The
majority of breast cancers have a phenotype that supports
origin from a cell(s) in the luminal compartment or from a cell
that was committed to this lineage. This is based on the
ability of the majority of breast carcinomas to form secretory
acinar structures with polarized epithelial cells that express
Figure 1
Normal breast duct and terminal duct lobular unit (TDLU) stained with
antibodies to cytokeratin (CK)5 and CK14. Note the coexpression of
these proteins that form a heterodimer. In this example the luminal cells
are the dominantly stained population in the TDLU, but in the duct the
myoepithelial cells are stained. Great variability can be seen both
within the same breast and between specimens.145
mucins on their luminal surface and have ultrastructural
characteristics of secretory cells. It is generally accepted that
breast cancers are clonal in their origin, but origin from a
single cell is difficult to prove because X-linked inactivation
studies have shown that the entire TDLU is clonal [22]. The
cellular origin of breast cancers therefore requires knowledge
of the normal lineages in the breast epithelium.
In order to establish the relationship between the
myoepithelial and luminal cells, O’Hare [23] developed
methods to isolate pure populations of these two cell types
using cell surface markers. These early studies indicated that
luminal cells and myoepithelial cells would proliferate as
isolated populations and that they would breed true. In 1999,
Petersen and coworkers [24] extended these studies and
demonstrated, with sorted luminal and myoepithelial cells,
that approximately 4% of cells, when placed in culture
conditions that supported myoepithelial cells, lost the luminal
marker CK18. Approximately 2% of cells gained expression
of the myoepithelial markers β4 integrin, CD10 and, later,
SMA. The myoepithelial lineage showed no signs of
conversion. In parallel with these studies, a number of
workers demonstrated that antibody KA1, which was
subsequently shown to recognize CK5 in association with
CK14 [25], labelled a subpopulation of luminal cells in the
TDLUs and basally located cells in the ducts [8,11]. Similar
findings were reported by Otterbach and coworkers [13] and
the group of Boecker and Buerger [14] using the
anticytokeratin antibody no 5/6 (Boehringer, Mannheim,
Germany). These observations have been extended by
Boecker and Buerger [14] and by Böcker and coworkers
[26] using in vivo multilabelling with CK8/18 and SMA as
markers of the terminal luminal and myoepithelial lineage to
generate a model in which the CK5+ cells are adult
progenitor cells, which go through transitions of intermediary
double labelling cells (CK5+/CK18/8+, CK+/SMA+) to
produce fully differentiated secretary luminal cells (CK18/8+)
and myoepithelial cells (SMA+). These data from the
laboratories of Petersen and Boecker indicate that the
putative stem cell is in the luminal/suprabasal compartment.
More sophisticated in vitro analyses followed on approaches
in the haemopoietic system, where stem cell populations are
defined by their ability to efflux the dye Hoechst 33342 [27].
Cells with this phenotype are called the ‘side population’ (SP)
and can be readily purified using flow cytometry. Vivanco and
coworkers [28] carried out the most comprehensive study to
date on the characterization of human breast cells within the
SP fraction. On isolation these cells do not express either the
luminal cell marker epithelial membrane antigen or the
myoepithelial marker common acute lymphoblastic leukaemia
antigen (CD10), but as single cells give rise to four types of
colonies, as assessed by their expression of CK18 and CK14
(CK18+, CK14+, CK18–/CK14– and CK18+/CK14+). These
findings parallel those of Welm and coworkers [29] in the
mouse, who also found that the SP fraction was originally null
for differentiation markers. Unfortunately, the report from
Vivanco and coworkers [28] does not allow for the fact that
CK14 is a marker of a subpopulation of luminal cells, and so
interpretation of these mixed phenotypes within the context of
differentiation into myoepithelial cells is difficult.
CK19 has also been proposed to be a stem cell or progenitor
marker. A recent report from Clarke and coworkers [30]
identified a CK19-positive, oestrogen receptor (ER)-positive
population of cells that have the capacity for self renewal. The
suprabasal putative precursor cells described by Petersen
and coworkers [31] were CK19-positive and may be the
same as those described by Clarke and colleagues [30]. This
may also be the ER-positive progenitor cell proposed by
Dontu and coworkers [32] in their model of human breast
progenitors. These observations are consistent with the
earlier findings reported by Taylor-Papadimitriou and
coworkers [33] on a CK19 subpopulation in the lobules of
the normal breast. These cell biological approaches detail the
complexities of the cell types in normal breast, but until these
hierarchies are better defined it is difficult to interpret current
knowledge in relation to immortalizing events and
heterogeneity in breast cancer. It is clear, however, that
breast cancers can be subclassified on the basis of their
molecular signature, regardless of the significance, if any, to
normal lineage phenotypes.
Carcinomas with ‘basal’ gene expression
have a distinct molecular signature
Perou and colleagues originally demonstrated that the
phenotypic diversity of breast carcinomas is reflected in
corresponding systematic variation in gene expression
patterns. Multiple independent studies have now demon-
strated that a subset of tumours in sporadic breast
carcinoma cohorts express a gene expression signature that
includes relatively high level expression of stratified epithelial
keratins (CK5 and CK17) [34-38]. As detailed below,
although breast tumours with an aggressive phenotype that
express these cytokeratins were previously characterized,
this subtype of tumour gained considerable notoriety with
their rediscovery by the use of cDNA microarrays. A
consistent biological theme is apparent in the genes that
distinguish these tumours, in that many encode proteins that
are expressed by normal stratified epithelia. Included in this
are genes that mediate cell–cell interactions (e.g. CDH3),
matrix remodelling genes (e.g. MMP14), and genes that
encode growth factor receptors (e.g. EGFR) and
extracellular matrix proteins (e.g. LAMA3 and  LAMC2). A
comparison of the gene expression patterns between breast-
derived tumours and cell lines in culture revealed that these
tumours share signatures with breast tumours classified as
‘luminal’ or ‘erbB2’ by expression of common epithelial
genes (e.g. CDH1 and  JUP) but are distinguished by
expression of the signature shared with cultured mammary
epithelial cells (human mammary epithelial cells and
immortalized normal breast epithelial cell lines) [39].
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Several lines of evidence from molecular studies support the
idea that these tumours are biologically distinct and may arise
through distinct oncogenic pathways. Analysis of a breast
cancer gene expression dataset that included both sporadic
patients and carriers of the BRCA1 mutation demonstrated a
strong association between BRCA1-related breast cancers
and expression of the ‘basal’ gene expression signature [35].
This was supported by a study conducted by Foulkes and
coworkers [40] that demonstrated an association between
BRCA1-related breast cancers and immunoreactive basal
CK5/6. Based on these observations, Foulkes [41] hypothe-
sized that BRCA1 is a stem cell regulator. The model
proposed by Behbod and Rosen [1] considers myoepithelial
differentiation as being end-stage and ‘basal-like’ tumours
arising from ER-negative long-term stem cells. This model
would indicate that the stratified cytokeratins are markers of
more than one cell population in the normal breast.
In addition, both cytogenetic and comparative genomic
hybridization analyses suggest that breast tumours that
express stratified epithelial keratins also have quantitative
genomic abnormalities that distinguish them from tumours
that express simple epithelial keratins [42,43]. Interestingly,
Jones and coworkers [44] identified two subgroups of CK14-
expressing tumours distinguished by cytogenetic differences.
This may be related to the so-called ‘normal’ breast subtype
identified in gene expression experiments that express gene
patterns similar to the basal signature [34,35] and/or the
subgroups of basal alluded to by Sortiriou and coworkers
[37]. Moll’s group and others [45] have pointed out that an
explanation for stratified cytokeratin expression may be found
in relation to squamous metaplasia. It is of interest in this
context that the basal signature also distinguishes squamous
cells from adenocarcinoma of the lung [46] and a subtype of
head and neck tumours with poor prognosis [47]. This
common signature in comparisons between tumours derived
from different origins suggests that these tumours may arise
in functionally related cell types that are unrelated to the
tissue of origin. This suggests that, analogous to the
classification of leukaemia subtypes, a novel classification of
carcinomas may emerge that relates subtypes to
differentiated cell types in normal epithelia that transcends
tissue of origin.
What is the clinical significance of cytokeratin
defined subtypes of breast cancer?
As it became clear that the various types of epithelial
differentiation in the body and the tumours from which they
were derived expressed different sets of cytokeratins, cyto-
keratin staining was rapidly applied in diagnostic pathology
[48]. It was also noted at about the same time that the
pattern of expression of CK5, CK14, and CK17 identified the
myoepithelial cells of in situ breast lesions, and therefore was
useful in distinguishing benign from malignant disease
[13,25]. The potential poor survival or early recurrence
associated with CK5/17 expression in tumour cells was first
reported by Dairkee and coworkers [49] in 1987. This
indicated that the tumours expressed phenotypes related to
normal luminal cells as well as to stratified epithelial keratins,
recapitulating the heterogeneity of the luminal cells in the
normal TDLU. In 1991 Wetzels and coworkers [11] took the
observations of Dairkee and colleagues forward with a
detailed analysis of keratins in benign and malignant breast
disease. In that study numerous antibodies were used against
individual cytokeratins. Using three antibodies that recognize
CK14 (i.e. LLO02, KA1 and EKH4), those investigators
demonstrated that with minor variations all the reagents
produced a similar pattern of immunoreactivity and that
breast cancers fell into two main groupings: 38% of
carcinomas expressed stratified epithelial cytokeratins (CK5,
CK14 and/or CK17) and the rest expressed only simple
epithelial keratins.
As pointed out by Moll and coworkers [12], the biological
significance of the differential expression of cytokeratin
polypeptides in breast carcinomas is unclear. Although we do
not know the functional role that cytokeratins CK5, CK14 and
CK17 play, it is clear that their expression is associated with
poor prognosis. Moll and colleagues examined the keratin
profile of 101 graded breast carcinomas. This is an important
study because it clearly indicated that there was a correlation
between grade and keratin profile, with grades 1 and 2 being
associated with simple keratins and high-grade tumours
being associated with the stratified epithelial keratins CK4,
CK14 and/or CK17 [12]. This keratin phenotype was also
associated with short overall and disease-free survival, and
ER negativity, particularly in the node positive cohort. All
tumours expressed simple epithelial cytokeratins (CK7, CK8,
CK18, or CK19) and 62% of the 45 grade 3 carcinomas had
a bimodal expression pattern, coexpressing at least one
stratified cytokeratin (CK4 36%, CK5 18%, CK14 20% and
CK17 38%). This important study, demonstrating the
coexpression of simple and stratified cytokeratin expression
in the same tumours, continued earlier work conducted by
Nagle and coworkers [8] in 1986, and was confirmed
recently by Abd El-Rehim and colleagues [50]. In this study
1944 carcinomas were examined, of which 98.8% were
positive for simple epithelial (luminal) keratins. Combined
luminal and basal cytokeratins were expressed in 27.4%,
basal alone in 0.8%, and 0.4% expressed neither.
Observations from Moll’s laboratory were recently extended
by numerous other investigators who have shown similar
correlations between poor prognosis and expression of CK5,
CK14 and CK17 [39,50,51]. Korsching and coworkers [43],
using immunohistochemical expression analysis of 15
proteins with hierarchical cluster analysis, extended these
findings to identify clinical subgroups. They confirmed that
CK5/6 immunoreactive tumours are generally negative for ER
and progesterone receptor, and form a clinical subgroup
distinct from c-erbB-2 expressing tumours. They also found a
strong correlation between this subgroup with increased
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expression of p53, epidermal growth factor receptor (EGFR)
and proliferative index. Other groups have described a
correlation between basal cytokeratin expression and atypical
and typical medullary carcinomas [52].
More recently, Nielsen and colleagues [53] took 21 tumours
that were defined as ‘basal’ by microarray, and performed an
immunohistochemical analysis with six distinguishing markers
(ER, CK5/6, CK17, EGFR, HER2, c-Kit). They concluded that
an immunohistochemical surrogate for gene array
experiments to identify ‘basal-like’ breast cancers is ER-
negative, HER2-negative/low, and CK5/6-positive and/or
HER1-positive. Thus, 16 out of 21 tumours expressing the
basal gene expression signature would have been identified
using these criteria, providing a sensitivity of 76% and a
specificity of 100%. It is clear from the discussion in this
paper that the term ‘basal-like tumour’ is still to be clearly
defined at the immunohistochemical level, because the
presence of basal cytokeratin positivity was not a require-
ment. There is a tendency to move toward a definition of a
basal-like tumour by exclusion on the basis that these
tumours are ER negative and c-erbB-2 negative. Because
there is no absolute correlation between HER1, c-Kit,
CK5/14/17, ER negativity and c-erbB-2 negativity, it may be
best to await standardization of methodologies, protocols and
agreements on reagents for immunocytochemistry before
new classifications are developed. For clinical purposes, it
would seem appropriate to reconsider the terminology and
that, instead of rigidly defining subgroups, a pragmatic
marker-driven approach is required.
The possibility that detection of basal-like tumours might be
relevant to development of tailored treatment approaches is
raised by their high level expression of EGFR and c-Kit, both
targets of recently approved therapies. An interesting study
conducted by Troester and coworkers [54] identified
chemotherapy-induced gene expression signatures in cell line
models of luminal epithelial tumours (MCF-7 and ZR-75-1)
and compared them with induced genes in telomerase-
immortalized cell line models of basal epithelial tumours. They
then identified gene expression signatures in comparison
between two samples from patients taken before and after 16
weeks of chemotherapy, including both luminal and basal
classified cases. It was intriguing in these very different
experimental approaches that they identified some genes
induced in common between basal cell lines and tumours
that were different from the individual genes in common
between ‘luminal’ cell lines and tumours. This suggests that
the physiological differences between luminal and basal
breast cancers may have implications for their response to
standard chemotherapy.
Conclusion
In this article we have tried to produce an overview of current
knowledge relating to cytokeratin expression and the basal
cell phenotype. Biochemical, immunohistochemical and gene
expression profiling technologies are inherently descriptive
and therefore do not directly address hypotheses on the
lineage of different cancer types. A definitive statement
cannot be made on the normal localization of cytokeratins,
and thus the use of cytokeratin expression to define
relationships between cells and the origins of cancer is
premature and might be misleading. Whatever the histogenic
relationships, if any, between the cells expressing CK5 and
CK14 and the group of tumours defined as ‘basal-like’, it is
clear that the combination of morphology and expression
profiling has defined a potentially important tumour subset
that can be identified as a poor prognostic group and should
be considered for individual management. The clustering data
have revealed a number of known and new potential targets
for diagnosis, predictive testing and therapy.
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